Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies

View ORCID ProfileBélène Podmore, Nawab Qizilbash, Alessandra Lacetera, Itziar Ubillos, Kirsty Andresen, Ana Roncero Martín, Jara Majuelos-Melguizo, Ana Cuñado Moral, Marina Hinojosa Campos, Jeffrey K Aronson, Stuart Pocock
doi: https://doi.org/10.1101/2021.04.23.21255815
Bélène Podmore
1OXON Epidemiology, Madrid, Spain
2London School of Hygiene & Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bélène Podmore
Nawab Qizilbash
1OXON Epidemiology, Madrid, Spain
2London School of Hygiene & Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n.qizilbash@oxonepi.com
Alessandra Lacetera
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Itziar Ubillos
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsty Andresen
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Roncero Martín
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jara Majuelos-Melguizo
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Cuñado Moral
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Hinojosa Campos
1OXON Epidemiology, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey K Aronson
3Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Pocock
2London School of Hygiene & Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To summarise and compare evidence from randomised controlled trials and observational studies of the effect of tocilizumab on in-hospital mortality in patients with covid-19.

Design Systematic review and meta-analysis.

Data sources Searches conducted in Embase and PubMed from July 2020 until 1 March 2021.

Study Selection Observational studies and randomised controlled trials (RCTs) assessing in-hospital mortality in patients receiving tocilizumab compared with standard care or placebo.

Data extraction The primary outcome was in-hospital mortality at 30 days. The risk of bias in observational studies was assessed using the ROBINS-I tool. A fixed effect meta-analysis was used to combine relative risks, with random effects and risk of bias as a sensitivity analysis.

Results Of 5,792 publications screened for inclusion, eight RCTs and 35 observational studies were identified. The RCTs showed an overall relative risk reduction in in-hospital mortality at 30 days of 0.86 (95% CI 0.78 to 0.96) with no statistically significant heterogeneity. 23 of the observational studies had a severe risk of bias, 10 of which did not adjust for potential confounders. The 10 observational studies with moderate risk of bias reported a larger reduction in mortality at 30-days (relative risk 0.72, 95% CI 0.64 to 0.81) but with significant heterogeneity (P<0.01).

Conclusion This meta-analysis provides strong evidence from RCTs that tocilizumab reduces the risk of mortality in hospitalised covid-19 patients. Observational studies with moderate risk of bias exaggerated the benefits on mortality two-fold and showed heterogeneity. Collectively observational studies provide a less reliable evidence base for evaluating treatments for covid-19.

What is already known on this topic

  • Early case reports suggested that tocilizumab might produce clinical and biochemical improvement in covid-19. This was followed by observational studies using retrospective data, largely supporting clinicians’ impressions of benefit.

  • This led to wider use of tocilizumab, despite failure to show benefit on all-cause mortality from early underpowered randomised controlled trials (RCTs) in severe covid-19. The RECOVERY trial, the largest trial, has recently shown clear overall benefit in hospitalised patients with covid-19.

What this study adds

  • This meta-analysis provides strong evidence from RCTs that tocilizumab reduces the risk of mortality in hospitalised covid-19 patients.

  • Observational studies with moderate risk of bias exaggerated the benefits on mortality by two-fold.

  • Collectively observational studies provide a less reliable evidence base for evaluating treatments for covid-19.

Competing Interest Statement

OXON Epidemiology is a scientific service provider of observational research, pragmatic trials and meta-analysis to the pharmaceutical industry.

Clinical Protocols

https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=184089

Funding Statement

The real-time systematic review process was partially funded by GSK. GSK had no involvement in the analysis of the data, writing of the manuscript or the decision or timing of its submission.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval not required as this is a systematic review.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Requests for data sharing should be sent to the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted April 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies
Bélène Podmore, Nawab Qizilbash, Alessandra Lacetera, Itziar Ubillos, Kirsty Andresen, Ana Roncero Martín, Jara Majuelos-Melguizo, Ana Cuñado Moral, Marina Hinojosa Campos, Jeffrey K Aronson, Stuart Pocock
medRxiv 2021.04.23.21255815; doi: https://doi.org/10.1101/2021.04.23.21255815
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies
Bélène Podmore, Nawab Qizilbash, Alessandra Lacetera, Itziar Ubillos, Kirsty Andresen, Ana Roncero Martín, Jara Majuelos-Melguizo, Ana Cuñado Moral, Marina Hinojosa Campos, Jeffrey K Aronson, Stuart Pocock
medRxiv 2021.04.23.21255815; doi: https://doi.org/10.1101/2021.04.23.21255815

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (943)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (419)
  • Epidemiology (8971)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (212)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10772)
  • Intensive Care and Critical Care Medicine (571)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1819)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1892)
  • Public and Global Health (4111)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)